| Literature DB >> 35199316 |
Keita Hattori1, Ryo Shimizu2, Shoichiro Tanaka2, Takashi Terashima2, Miya Hiramatsu2, Taishi Shimomura2, Takeshi Ito2, Takatoshi Morinaga2, Mika Terasaki3, Akira Shimizu3, Kunio Morozumi4, Hirofumi Tamai2.
Abstract
Fibrillary glomerulonephritis (FGN) is a rare glomerular disease. FGN is characterized by the deposition of randomly arranged, nonbranching microfibrils in the mesangium and glomerular basement membrane. The discovery of DNAJ homolog subfamily B member 9 (DNAJB9) in 2017 was a breakthrough, and DNAJB9 has been proven to be extremely useful for the definitive diagnosis of FGN. While FGN often occurs in middle-aged individuals, this case was diagnosed at a relatively young age of 17. We performed renal biopsy, and light microscopic study revealed mesangial proliferation with expansion and subepithelial deposits. Electron microscopic study showed glomerular deposition of randomly oriented nonbranching fibrils with a mean of 20 nm. However, direct first scarlet stain for amyloidosis was weakly positive. Therefore, we confirmed the diagnosis of FGN and eliminated the presence of amyloidosis with mass spectrometry. This is the first case in Japan in which the complication of amyloidosis was ruled out with mass spectrometry and FGN was diagnosed using immunostaining and mass spectrometry of DNAJB9. We began treatment with cyclosporine A. One and a half years after the start of the treatment, kidney function continues to be normal.Entities:
Keywords: Cyclosporine A; DNAJB9; Fibrillary glomerulonephritis; Juvenile-onset; Mass spectrometry
Year: 2022 PMID: 35199316 DOI: 10.1007/s13730-022-00693-3
Source DB: PubMed Journal: CEN Case Rep ISSN: 2192-4449